Development Of Substituted Pyrido[3,2-D]Pyrimidines As Potent And Selective Dihydrofolate Reductase Inhibitors For Pneumocystis Pneumonia Infection

KL
Kramer Levin Naftalis & Frankel LLP

Contributor

Kramer Levin provides its clients proactive, creative and pragmatic solutions that address today’s most challenging legal issues. The firm is headquartered in New York with offices in Silicon Valley and Paris and fosters a strong culture of involvement in public and community service. For more information, visit www.kramerlevin.com
Intellectual Property scientific advisor Khushbu Shah co-authored an article titled "Development of Substituted Pyrido[3,2-d]Pyrimidines as Potent and Selective Dihydrofolate Reductase
United States Food, Drugs, Healthcare, Life Sciences

Intellectual Property scientific advisor Khushbu Shah co-authored an article titled "Development of Substituted Pyrido[3,2-d]Pyrimidines as Potent and Selective Dihydrofolate Reductase Inhibitors for Pneumocystis Pneumonia Infection" which was published in ScienceDirect on June 4, 2019. The article discusses efforts to develop novel compounds that can provide safer treatment for pneumocystis pneumonia infection.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More